Johnson & Johnson reported better-than-expected third-quarter sales and raised its full-year revenue guidance.

Operator Good morning and welcome to Johnson & Johnson's third quarter 2024 earnings conference call. All participants will ...

Johnson & Johnson (JNJ) stock fell as the company lowered full-year earnings outlook while reporting better-than-expected Q3 ...

Johnson & Johnson's stock was up in premarket trades Tuesday after the drugmaker reported better-than-expected third-quarter ...

Johnson & Johnson (NYSE:JNJ) is scheduled to announce Q3 earnings results on Tuesday, October 15th, before market open.

We expect the company to post revenue of $22.2 billion and earnings of $2.20 per share, broadly aligning with the consensus ...

Johnson & Johnson (NYSE: JNJ) recently reported its Q3 results, with revenues and earnings exceeding our estimates.

Johnson & Johnson's Q3 results exceeded expectations, with 26.5% year-over-year growth in the cardiovascular market and a 5.4 ...

Johnson & Johnson's Q3 2024 results surpassed analyst expectations, reporting $2.42 EPS and $22.47 billion in sales. Updated ...

David Risinger, an analyst from Leerink Partners, maintained the Buy rating on Johnson & Johnson (JNJ – Research Report). The ...

Johnson & Johnson expects full-year earnings in the range of $9.88 to $9.98 per share, with revenue in the range of $88.4 billion to $88.8 billion. This story was generated by Automated Insights ( ...

Johnson & Johnson (JNJ) revealed a profit for third quarter that decreased from the same period last year but beat the Street ...